Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 6/20 | 0.55 |
| ▸ | GAA | P10253 | 2/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | ATM | Q13315 | 1/20 | 0.54 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.54 |
| ▸ | ACHE | P22303 | 1/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | KDM1A | O60341 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | HTR1A | P08908 | 1/20 | 0.48 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.48 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | IDO1 | P14902 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2119957 | 0.98 | GAA (0.59) | SIGMAR1GAAMAPTATMTAAR1 | |
| SCHEMBL7460981 | 0.89 | ALDH1A1 (0.53) | SIGMAR1GAAMAPTTAAR1ACHE | |
| SCHEMBL10063072 | 0.88 | SIGMAR1 (0.67) | SIGMAR1KCNH2 | |
| SCHEMBL30614498 | 0.80 | TAAR1 (0.57) | GAATAAR1ACHECYP1A2CYP2D6 | |
| SCHEMBL283735 | 0.79 | SIGMAR1 (0.81) | SIGMAR1GAAMAPTATMTAAR1 | |
| SCHEMBL2238594 | 0.79 | CA12 (0.57) | SIGMAR1GAAMAPTATMTAAR1 | |
| SCHEMBL7103006 | 0.79 | SIGMAR1 (0.55) | SIGMAR1GAAMAPTATMTAAR1 | |
| N-Benzylpropargylamine SCHEMBL669952 | 0.78 | PYCR1 (0.64) | SIGMAR1GAAMAPTCYP1A2CYP3A4 | |
| SCHEMBL17667767 | 0.78 | SIGMAR1 (0.53) | SIGMAR1GAAMAPTATMTAAR1 | |
| SCHEMBL13937400 | 0.77 | SIGMAR1 (0.77) | SIGMAR1GAAMAPTATMTAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118406200-A | Silver-based hybrid material and preparation method and application thereof | 安徽工业大学 | 2024-07-30 | — | — | CN | claimed |
| CN-117160463-A | Preparation method and application of cerium oxide supported copper-based catalyst | 北京化工大学 | 2023-12-05 | — | — | CN | claimed |
| EP-2531181-A1 | EXTENDED RELEASE FORMULATIONS OF RASAGILINE AND USES THEREOF | Pharma Two B Ltd. (IL) | 2012-12-12 | — | — | EP | claimed |
| EP-2531033-A1 | DIHYDROPYRIDOPHTHALAZINONE INHIBITORS OF POLY(ADP-RIBOSE) POLYMERASE (PARP) FOR USE IN TREATMENT OF DISEASES ASSOCIATED WITH A PTEN DEFICIENCY | BioMarin Pharmaceutical Inc. (US) | 2012-12-12 | — | — | EP | claimed |
| CN-118406200-A | Silver-based hybrid material and preparation method and application thereof | 安徽工业大学 | 2024-07-30 | — | — | CN | disclosed |
| CN-115975096-A | Can catalyze CO in industrial waste gas 2 Copper-based N-heterocyclic carbene porous polymer converted into oxazolidinone, and preparation method and application thereof | 桂林电子科技大学 | 2023-04-18 | — | — | CN | disclosed |
| CN-109069414-B | Igemeine for the treatment of neurodegenerative diseases | 西格马瑟拉公司 | 2022-01-14 | — | — | CN | disclosed |
| EP-3903767-A1 | IGMESINE FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | SigmaThera SAS (FR) | 2021-11-03 | — | — | EP | disclosed |
| US-11129801-B2 | Igmesine for use in the treatment of neurodegenerative diseases | SIGMATHERA SAS (FR) | 2021-09-28 | — | — | US | disclosed |
| EP-3413870-B1 | IGMESINE FOR USE IN THE TREATMENT OF ALZHEIMER'S DISEASE | SIGMATHERA SAS (FR) | 2021-08-04 | — | — | EP | disclosed |
| EP-3517103-A1 | EXTENDED RELEASE FORMULATIONS OF RASAGILINE AND USES THEREOF | Pharma Two B Ltd. (IL) | 2019-07-31 | — | — | EP | disclosed |
| EP-2531181-B1 | EXTENDED RELEASE FORMULATIONS OF RASAGILINE AND USES THEREOF | PHARMA TWO B LTD (IL) | 2019-04-10 | — | — | EP | disclosed |
| WO-2005056513-A1 | ASYMMETRIC IMINE HYDROGENATION PROCESSES | ABDUR-RASHID KAMALUDDIN (CA) | 2005-06-23 | — | — | WO | disclosed |
| WO-2005051371-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF CARDIOVASCULAR DISORDERS AND DISEASES | TECHNION RESEARCH & DEVELOPMENT FOUNDATION LTD. (IL) | 2005-06-09 | — | — | WO | disclosed |
| WO-2004082706-A2 | IFN-BETA ALONE OR IN COMBINATION WITH OTHER MEDICAMENTS FOR TREATING ALZHEIMER'S DISEASE AND DEMENS DISORDERS | ARES TRADING S.A. (CH) | 2004-09-30 | — | — | WO | disclosed |
| US-20030195260-A1 | Methods and pharmaceutical compositions employing S(+)-desmethylselegiline to treat neoplastic diseases or conditions | DISANTO ANTHONY R (US) | 2003-10-16 | — | — | US | disclosed |
| US-20030191191-A1 | Methods for preventing and treating peripheral neuropathy by administering desmethylselegiline delivery compositions | SOMERSET PHARMACEUTICALS, INC. | 2003-10-09 | — | — | US | disclosed |
| US-6528082-B2 | Both malignant and benign neoplasms | SOMERSET PHARMACEUTICALS, INC. | 2003-03-04 | — | — | US | disclosed |
| US-20020037930-A1 | Both malignant and benign neoplasms | SOMERSET PHARMACEUTICALS, INC. | 2002-03-28 | — | — | US | disclosed |
| WO-2002019964-A2 | METHODS AND PHARMACEUTICAL COMPOSITIONS EMPLOYING DESMETHYLSELEGILINE TO TREAT NEOPLASTIC DISEASES OR CONDITIONS | SOMERSET PHARMACEUTICALS, INC. (UM) | 2002-03-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030195260-A1 | Methods and pharmaceutical compositions employing S(+)-desmethylselegiline to treat neoplastic diseases or conditions | PYGL, SRM, SMS | SIGMAR1 2245/4885GAA 132/4885MAPT 2453/4885 |
| US-11129801-B2 | Igmesine for use in the treatment of neurodegenerative diseases | CLN6, MSN, PMP22 | SIGMAR1 2385/4885GAA 337/4885MAPT 20/4885 |
| US-20020037930-A1 | Both malignant and benign neoplasms | BRCA1, KRAS, VHL | SIGMAR1 2009/4885GAA 569/4885MAPT 4012/4885 |
| US-20030191191-A1 | Methods for preventing and treating peripheral neuropathy by administering desmethylselegiline delivery compositions | RECQL, SMN1; SMN2, PRPH | SIGMAR1 2631/4885GAA 1351/4885MAPT 1718/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.